M8 Pharmaceuticals

About M8 Pharmaceuticals

M8 Pharmaceuticals, formerly known as Moksha8, operates as a specialty biopharmaceutical company with a sharp focus on the Latin American market, primarily Brazil and Mexico. Founded in 2007 by Simba Gill and TPG Biotechnology, the firm was established to bridge the gap in access to high-value therapeutics in the region. In December 2023, Swiss pharmaceutical company Acino completed its acquisition of M8, a move designed to significantly expand Acino's footprint in Latin America and diversify its portfolio. Following the acquisition, M8's then-CEO Joel Barlan, who joined in 2014, was appointed as Head of the LATAM region for the combined entity. Barlan's extensive experience in the Latin American pharmaceutical sector, including leadership roles at Sanofi and UCB, has been instrumental in shaping the company's trajectory.

The company's business model is centered on strategic partnerships with global pharmaceutical and biotech companies to license, market, and distribute their products in Latin America. This model allows M8 to act as a commercialization partner, handling the entire continuum from go-to-market strategy and regulatory registration to sales, marketing, and long-term market presence. M8 serves a diverse range of clients, from large multinational corporations like Janssen and UCB to smaller innovators, by navigating the complex regulatory and market dynamics of the region. Revenue is generated through these exclusive promotion, distribution, and commercialization agreements.

M8's product portfolio is extensive, covering a wide array of therapeutic areas such as Central Nervous System (CNS), respiratory, cardiometabolism, oncology, gastroenterology, and rare diseases. The firm has successfully brought numerous established and innovative treatments to market. Notable partnerships include agreements with Janssen for a CNS portfolio featuring brands like Concerta® and Risperdal®, and with UCB for respiratory and CNS products including Atarax® and Xuzal®. More recent collaborations, post-acquisition, include an agreement with LG Chem for type 2 diabetes and osteoarthritis treatments, and with Supernus for Qelbree®, a treatment for ADHD. This strategy of in-licensing allows M8 to build a robust pipeline and solidify its position in key therapeutic segments, such as becoming a market leader in the CNS space in Latin America.